WO2011009757A3 - Use of human beta-defensin to influence the natural pigmentation process - Google Patents

Use of human beta-defensin to influence the natural pigmentation process Download PDF

Info

Publication number
WO2011009757A3
WO2011009757A3 PCT/EP2010/060026 EP2010060026W WO2011009757A3 WO 2011009757 A3 WO2011009757 A3 WO 2011009757A3 EP 2010060026 W EP2010060026 W EP 2010060026W WO 2011009757 A3 WO2011009757 A3 WO 2011009757A3
Authority
WO
WIPO (PCT)
Prior art keywords
defensin
influence
human beta
pigmentation process
natural pigmentation
Prior art date
Application number
PCT/EP2010/060026
Other languages
German (de)
French (fr)
Other versions
WO2011009757A2 (en
Inventor
Melanie Giesen
Sabine GRÜDL
Guido Fuhrmann
Original Assignee
Henkel Ag & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Ag & Co. Kgaa filed Critical Henkel Ag & Co. Kgaa
Publication of WO2011009757A2 publication Critical patent/WO2011009757A2/en
Publication of WO2011009757A3 publication Critical patent/WO2011009757A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of at least one human beta-defensin, the analogues thereof or agents that can stimulate expression of human beta-defensins, in order to influence the natural pigmentation process of skin and/or skin appendages.
PCT/EP2010/060026 2009-07-23 2010-07-13 Use of human beta-defensin to influence the natural pigmentation process WO2011009757A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102009027953.9 2009-07-23
DE102009027953 2009-07-23
DE102009044970A DE102009044970A1 (en) 2009-07-23 2009-09-24 Use of human beta-defensin to influence the natural pigmentation process
DE102009044970.1 2009-09-24

Publications (2)

Publication Number Publication Date
WO2011009757A2 WO2011009757A2 (en) 2011-01-27
WO2011009757A3 true WO2011009757A3 (en) 2011-03-31

Family

ID=43384052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/060026 WO2011009757A2 (en) 2009-07-23 2010-07-13 Use of human beta-defensin to influence the natural pigmentation process

Country Status (2)

Country Link
DE (1) DE102009044970A1 (en)
WO (1) WO2011009757A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009044970A1 (en) 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Use of human beta-defensin to influence the natural pigmentation process
EP3120850B1 (en) * 2012-12-14 2018-11-07 Unilever N.V. Niacinamide for inducing generation of antimicrobial peptides
WO2015195677A1 (en) * 2014-06-18 2015-12-23 Medicell Technologies, Llc Stem cell stimulating compositions and methods
RS63786B1 (en) 2015-12-15 2022-12-30 Medicell Technologies Llc Stem cell stimulating compositions and methods of treating melasma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103037A2 (en) * 2005-03-29 2006-10-05 Henkel Kommanditgesellschaft Auf Aktien COMPOSITION CONTAINING β-DEFENSIN 2
WO2008028779A1 (en) * 2006-09-06 2008-03-13 Henkel Ag & Co. Kgaa Method for the molecular characterization of old-age hair

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3725030A1 (en) 1987-07-29 1989-02-09 Henkel Kgaa SURFACE ACTIVE HYDROXYSULFONATE
US5136093A (en) 1991-02-06 1992-08-04 Smith Ronald J Quaternized panthenol compounds and their use
DE4413686C2 (en) 1994-04-20 1996-10-24 Henkel Kgaa Cationic sugar surfactants, process for their preparation and their use
FR2843125B1 (en) 2002-08-02 2012-11-16 Coletica ACTIVE PRINCIPLES STIMULATING HUMAN BETA-DEFENSIVE TYPE 2 AND / OR TYPE 3, AND COSMETIC OR PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENTS
DE102009044970A1 (en) 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Use of human beta-defensin to influence the natural pigmentation process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103037A2 (en) * 2005-03-29 2006-10-05 Henkel Kommanditgesellschaft Auf Aktien COMPOSITION CONTAINING β-DEFENSIN 2
WO2008028779A1 (en) * 2006-09-06 2008-03-13 Henkel Ag & Co. Kgaa Method for the molecular characterization of old-age hair

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANDILLE SOPHIE I ET AL: "A -defensin mutation causes black coat color in domestic dogs.", SCIENCE (NEW YORK, N.Y.) 30 NOV 2007 LNKD- PUBMED:17947548, vol. 318, no. 5855, 30 November 2007 (2007-11-30), pages 1418 - 1423, XP002610513, ISSN: 1095-9203 *

Also Published As

Publication number Publication date
DE102009044970A1 (en) 2011-01-27
WO2011009757A2 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
WO2011009759A3 (en) Use of dihydroquercetin and at least one amino acid to positively influence the natural pigmentation process
PL2640352T3 (en) Collagen hydrolysate used to improve the health of human skin, hair and/or nails
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
HK1162540A1 (en) Peptides for use in cosmetic or pharmaceutical treatment of the skin, mucous membranes and/or scalp //
ZA201202705B (en) Peptides used in the treatment and/or care of the skin.mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
FR2969495B1 (en) EXTRACT OF MACA-RICH AERIAL PARTS OF POLYPHENOLS AND COMPOSITION COMPRISING THE SAME
IL219318A (en) 3,5-dimethoxy-4'-hydroxystilbene (pter) for use in the treatment of skin diseases , damages or injuries and process for preparing the same
MX2018004616A (en) Cosmetic composition having probiotic bacteria.
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
TN2015000520A1 (en) Pharmaceutical compositions comprising collagen and sodium hyaluronate
IL212567A (en) Zeaxanthin, optionally combined with rutin, spermidine or both, for treating scalp disorders, uses thereof in the preparation of pharmaceutical, dietary or cosmetic compositions for treating scalp disorders and pharmaceutical, dietary or cosmetic compositions comprising the same
EP2274411A4 (en) Xanthohumol compositions and methods for treating skin diseases or disorders
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
EP2537513A3 (en) Use of anogeissus extract for fibrillin production in skin
HK1124779A1 (en) Use of an unsaponifiable extract of plant pulp in the treatment of skin ageing
WO2011009757A3 (en) Use of human beta-defensin to influence the natural pigmentation process
WO2011009758A3 (en) Use of purine and/or a purine derivative and at least one oligonucleotide to influence the natural pigmentation process
WO2011009763A3 (en) Cosmetic containing purine and/or a purine derivative and sclareol
WO2011035945A3 (en) Use of a combination of carnitine and/or a carnitine derivative with purine and/or a purine derivative for influencing the natural pigmentation process
WO2014045065A3 (en) Dietary compositions and their uses
WO2011009761A3 (en) Use of carnitine and dihydroquercitin to positively influence the natural pigmentation process
ZA201804198B (en) Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body
EP2404611A4 (en) Peptide for the prophylactic or therapeutic treatment of skin tumours in initial stages
PT2509944E (en) Novel peroxide derivatives, their process of preparation and their use in human medicine and in cosmetics for the treatment or prevention of acne
EP2902024A4 (en) Synergic composition of nitazoxanide and mebendazole, methods for the preparation thereof, and use of said composition for the treatment of human parasitosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10731524

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10731524

Country of ref document: EP

Kind code of ref document: A2